drugset / Trial / NCT01635829

A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

NCT01635829

Phase 1 Completed 24 enrolled Janssen Infectious Diseases BVBA
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the potential pharmacokinetic (what the body does to the drug) interactions between multiple doses of phenytoin 200 mg every 12 hours or carbamazepine 200 mg every 12 hours and telaprevir 750 mg every 8 hours at steady-state (constant concentration of medication in the blood) in healthy participants.

Timeline

Start
2012-05
Primary completion
2012-08
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule 200 mg Oral
Subject Phenytoin Unknown 200 mg Oral
Subject Telaprevir Small molecule 750 mg Oral

Indications

No indication recorded.